Johnson & Johnson on Tuesday forecast 2019 sales that fell short of analysts’ estimates as the healthcare conglomerate faces increasing competition for some of its older drugs. Read More

By Ian Dei

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.